Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women

Maturitas

Volumn 50, Issue 1, 2005, Pages 39-43

  Martínez, Carlos ^a   Basurto, Lourdes ^a   Zárate, Arturo ^a   Saucedo, Renata ^a   Gaminio, Elizabeth ^a   Collazo, Juan ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Coagulation factors; Fibrinolysis; Hormonal replacement therapy; Menopause; Thrombotic risk factors; Transdermal estrogens

Indexed keywords

ANTIGEN; ANTITHROMBIN III; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7A; ESTRADIOL; FIBRINOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; RECOMBINANT THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; POSTMENOPAUSE; RISK ASSESSMENT; THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYSTERECTOMY; LUTEINIZING HORMONE; MIDDLE AGED; PLASMINOGEN; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 10044220827     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.03.011     Document Type: Article

References (28)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
2. Grodstein F., Stampfer M.J., Goldhaber S.Z., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987
3. Meinlahn E.N., Kuller L.H., Matthews K.A., Kiss J.E. Haemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol. 2:1992;445-455
4. Spiliotopoulou I., Grouzi E. Hormone replacement therapy and thrombotic risk: effects on haemostasis, and the risk of venous thromboembolism. Haema. 6:2003;166-175
5. Grady D., Herrington D., Bitlner V., et al. for the HERS research group. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 288:2002;49-57
6. Grady D., Wenger N.K., Herrington D., Khan S., Furberg C., Hunninghake D. Postmenopausal hormone therapy increases risk of venous thromboembolic disease. The Heart and Estrogen/progestin replacement study. Ann Intern. Med. 132:2000;689-696
7. Hoibraaten E., Abdelnoor M., Sandset P.M. Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thromb. Haemost. 82:1999;1218-1221
8. Varas-Lorenzo C., García R.L., Cattaruzzi C., Troncon M.G., Agostinis L., Perez G.S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study in southern Europe. Am J. Epidemiol. 147:1998;387-390
9. Scarabin P.Y., Oger E. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 362:2003;428-432
10. Connard J., Mirabel C., Gompel A., Basdevant A., Pelissier C. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertil. Steril. 68:1997;449-453
11. Hoibraaten E., Qvigstad E., Andersen T.O., Mowinckel M.C., Sandset P.M. The effects of hormone replacement therapy (HRT) on haemostatic variables in women with previous venous thromboembolism results from a randomized, double-blind, clinical trial. Thromb. Haemost. 85:2001;775-781
12. Demirol A., Baykal C., Kirazli S., Ayhan A. Effects of hormone replacement on hemostasis in spontaneous menopause. Menopause. 8:2001;135-140
13. Lowe G.D.O., Upton M.N., Rumley A., McConnachie A., O'Reilly D.J.O., Watt G.C.M. Differents effects of oral and transdermal hormone replacement therapies on factor I.X., APC resistance, t-PA, PAI and C reactive protein. A cross-sectional population survey. Thromb. Haemost. 86:2001;550-556
14. Vehkavaara S., Silveira A., Hakala-Ala-Pietila T., et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb. Haemost. 85:2001;619-625
15. Scarabin P.Y., Alhenc-Gelas M., Plu-Bureau G., et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb. Vasc. Biol. 17:1997;3071-3078
16. Glueck C.J., Wang P., Fontaine R.N., Tracy T., Sieve-Smith L., Lang J.E. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden Mutation (resistance to activated protein C). Am J. Cardiol. 84:1999;549-554
17. Khosla S., Owen W.G., Miller V.M. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation an inflammation in postmenopausal women. J. Clin Endocrinol. Metab. 86:2001;3629-3634
18. Clauss A. Gerinnungsphysiologische Schnellmethode zur Be-stimmmung des fibronogens. Acta Haematol. 17:1957;234-236
19. Lee A.J., Lowe G.O.D., Smith W.C.S., Turnstall-Pedoe H. Plasma fibrinogen in women relationships with oral contraception, the menopause and hormone replacement therapy. Br J. Haematol. 83:1993;612-621
20. Zegura B., Keber I., Sebestjen M., Koening W. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis. 168:2003;123-129
21. Chen F.P., Lee N., Soong Y.K., Huang K.E. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. Menopause. 8:2001;347-352
22. Bladbjerg E.M., Skouby S.O., Andersen L.F., Jespersen J. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod. 17:2002;3235-3241
23. Scarabin P.Y., Vissac A.M., Kirtzin J.M., et al. Popu0lation correlates of coagulation factor VII: importance of age, sex, and menopausal status as determinants of activated FVII. Atheroscler Thromb. Vasc Biol. 16:1996;170-176
24. Thogersen A.M., Jansson J.H., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 98:1998;2241-2247
25. Lip G.Y., Felmeden D.C. Hormone replacement therapy and cardiovascular risk: do abnormalities of coagulation and fibrinolysis matter? J. Intern. Med. 249:2001;201-204
26. Vasalli J.D., Sappino A.P., Belin D. The plasminogen activator/plasmin system. J. Clin Invest. 88:1991;1067-1072
27. Koh K.K., Mincemoyer R., Bui M.N., et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl. J. Med. 336:1997;683-690
28. Tatovic-Babic D., Beljic T., Drezgic M., et al. Effect of postmenopausal hormone substitution on the lipid profile and coagulation factors in female smokers. Srp. Arh. Celok. Lek. 130:2002;371-375